Literature DB >> 15045498

Circulating levels of cyclosporin A in inflammatory bowel disease: relationships with lymphocyte inhibition and the age of patients.

Giulia Angeloni1, Miriam Latteri, Raffaele Manna, Carlo Rumi, Giovanni Gasbarrini, Pierluigi Navarra.   

Abstract

OBJECTIVE: To determine in the same blood sample the concentrations of cyclosporin A (CsA) and the degree of CsA-induced lymphocyte inhibition; to establish a relationship between these parameters; and to investigate the factor(s) influencing such a putative relationship.
METHODS: Ten patients with a diagnosis of Crohn's disease (n=7) or ulcerative colitis (n=3) were enrolled in the study. The patients, who had never been immunosuppressed, were treated with microemulsion CsA twice daily by the oral route; at steady-state, blood samples were collected 0, 0.5, 1, 2, 3, 5, 7 and 12 h after the morning dose. CsA blood levels were measured by means of radioimmunoassay. The percentages of lymphocytes during the S-phase were assessed by flow-cytometry on the same blood specimens, only for samples collected at 0 h and 2 h.
RESULTS: An inverse relationship emerged between CsA blood concentrations and the percentage of lymphocytes during the S-phase: the latter was maximal before the beginning of treatment and minimal in association with peak CsA levels. Furthermore, a highly significant correlation was found between trough CsA levels and the age of the patient, since the percentage of inhibited lymphocytes increases with age.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15045498     DOI: 10.1007/s00228-004-0743-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  In-vitro cyclosporin sensitivity of proliferating lymphocytes is predictive of in-vivo therapeutic response in ulcerative colitis.

Authors:  G McCormack; D O'Donoghue; A Baird
Journal:  Aliment Pharmacol Ther       Date:  2001-05       Impact factor: 8.171

2.  CD4 and CD8 cytokine-producing T cells are transiently reduced following cyclosporine intake: maximal inhibition occurs at 2 hours coincidental with drug C(max).

Authors:  J R Mora; M R Bono; M Rosemblatt; S Rodriguez; J Morales; E Buckel; A Fierro
Journal:  Transplant Proc       Date:  2001 Nov-Dec       Impact factor: 1.066

Review 3.  Rejection and recipient age.

Authors:  Benjamin A Bradley
Journal:  Transpl Immunol       Date:  2002-08       Impact factor: 1.708

4.  Evidence that calcineurin is rate-limiting for primary human lymphocyte activation.

Authors:  T D Batiuk; L Kung; P F Halloran
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

5.  Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease.

Authors:  M Latteri; G Angeloni; N G Silveri; R Manna; G Gasbarrini; P Navarra
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Evaluation of a new whole blood cytometric lymphocyte transformation test for immunological screening.

Authors:  S Bussa; C Rumi; G Leone; B Bizzi
Journal:  J Clin Lab Immunol       Date:  1993

Review 7.  Calcineurin and the biological effect of cyclosporine and tacrolimus.

Authors:  P F Halloran; L Kung; J Noujaim
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

8.  Differential effects of interleukin-2 blockade on apoptosis in naïve and activated human lymphocytes.

Authors:  Kenneth J Woodside; Mingdao Hu; Tao Meng; Glenn C Hunter; Laurie E Sower; John A Daller
Journal:  Transplantation       Date:  2003-05-27       Impact factor: 4.939

9.  Pentoxifylline potentiates in vitro lymphocyte suppression by glucocorticoids and immunosuppressive drugs.

Authors:  W A Briggs; J Eustace; S Mathew; L F Gimenez; M Choi; P J Scheel; J Burdick
Journal:  J Clin Pharmacol       Date:  1998-06       Impact factor: 3.126

10.  Immunopharmacodynamic studies of cyclosporine in patients awaiting renal transplantation.

Authors:  C H d'Uscio; F T Aweeka; T Prueksaritanont; S J Tomlanovich; S K Gupta; M V Lantz; J G Gambertoglio; M R Garovoy; L Z Benet
Journal:  J Clin Pharmacol       Date:  1995-10       Impact factor: 3.126

View more
  1 in total

Review 1.  The role of tacrolimus in inflammatory bowel disease: a systematic review.

Authors:  Yago Gonzalez-Lama; Javier P Gisbert; Jose Mate
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.